Format

Send to

Choose Destination
Peptides. 1994;15(3):461-6.

Cyclic lactam analogues of ovine pituitary adenylate cyclase activating polypeptide (PACAP): discovery of potent type II receptor antagonists.

Author information

1
Department of Medicine, Tulane University Medical Center, New Orleans, LA 70112.

Abstract

Binding of [125I]PACAP-38 to rat liver membranes was investigated. It was rapid at 37 degrees C, reversible, and saturable, and it was time, concentration, and temperature dependent. Scatchard plots showed that [125I]PACAP-38 bound to single noninteracting site(s), and [125I]VIP bound to high- and low-affinity binding site(s). The order of potency of displacing [125I]PACAP-38 from rat liver membranes was: PACAP-38 > PACAP-27 > VIP (IC50 = 5, 180, and 350 nM, respectively). Surprisingly, the order of potency of displacing [125I]VIP was also the same (IC50 = 1, 8, and 52 nM, respectively). The order of potency of stimulating adenylate cyclase to release cyclic AMP was: PACAP-27 > VIP > PACAP-38 (EC50 = 0.06, 1, and 6 nM, respectively). Modification of PACAP-27 or PACAP-38 structures either through deletions, substitutions, or cyclization involving amino acid residues, Asp3, Asp8, Lys15, Lys20, or Lys21 indicated that the N-terminal region of the molecule is important for both binding and transduction. Of the various lactam analogues synthesized, cyclo[Asp3,Lys15]PACAP-38 and cyclo[Asp8,Lys15]PACAP-38 appear to be competitive receptor antagonists of the release of cAMP by PACAP-38. The results presented suggest that liver membranes possess distinct PACAP and VIP receptors, and that the PACAP receptor(s) is probably similar, but not identical, to type I receptor(s) characteristic of the brain.

PMID:
7937320
DOI:
10.1016/0196-9781(94)90206-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center